A to-do list for the new FDA commissioner

New England Journal of Medicine

Volumn 360, Issue 14, 2009, Pages 1373-1378

  Okie, Susan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; HEPARIN; ROFECOXIB; VACCINE;

CLINICAL EFFECTIVENESS; DECISION MAKING; DRUG APPROVAL; DRUG MARKETING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; FOOD SAFETY; GOVERNMENT; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HUMAN; MARKET; MEDICAL SPECIALIST; NEOPLASM; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RISK FACTOR; SHORT SURVEY; UNITED STATES; ARTICLE; CATERING SERVICE; ECONOMICS; HISTORY; LEGAL ASPECT; ORGANIZATION AND MANAGEMENT; SAFETY; STANDARD;

DEVICE APPROVAL; FOOD SUPPLY; HEALTH POLICY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; NEW YORK CITY; PUBLIC HEALTH ADMINISTRATION; SAFETY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 63849221325     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp0810755     Document Type: Article

References (5)

1. Harris G. Report criticizes F.D.A. on device testing. New York Times. January 16, 2009:A15.
2. FDA Science Board. FDA science and mission at risk: report of the Subcommittee on Science and Technology. Bethesda, MD: Food and Drug Administration, November 2007.
3. Green M, Jolin M, eds. Change for America: a progressive blueprint for the 44th president. New York: Basic Books, 2009.
4. Drug safety: better data management and more inspections are needed to strengthen FDA's foreign drug inspection program. Washington, DC: Government Accountability Office, September 2008. (Publication no. GAO-08-970.)
5. Medical devices: FDA should take steps to ensure that high-risk device types are approved through the most stringent premarket review process. Washington, DC: Government Accountability Office, January 2009. (Publication no. GAO-09-190.)